<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1697</journal-id><journal-id journal-id-type="pmc-domain">cpaa</journal-id><journal-id journal-id-type="publisher-id">Clinical Pharmacology: Advances and Applications</journal-id><journal-title-group><journal-title>Clinical Pharmacology : Advances and Applications</journal-title></journal-title-group><issn pub-type="epub">1179-1438</issn><publisher><publisher-name>Dove Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4948726</article-id><article-id pub-id-type="pmcid-ver">PMC4948726.1</article-id><article-id pub-id-type="pmcaid">4948726</article-id><article-id pub-id-type="pmcaiid">4948726</article-id><article-id pub-id-type="pmid">27471411</article-id><article-id pub-id-type="doi">10.2147/CPAA.S102676</article-id><article-id pub-id-type="publisher-id">cpaa-8-083</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Rambiritch</surname><given-names initials="V">Virendra</given-names></name><xref ref-type="aff" rid="af1-cpaa-8-083">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Naidoo</surname><given-names initials="P">Poobalan</given-names></name><xref ref-type="aff" rid="af2-cpaa-8-083">2</xref><xref ref-type="corresp" rid="c1-cpaa-8-083"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maharaj</surname><given-names initials="B">Breminand</given-names></name><xref ref-type="aff" rid="af1-cpaa-8-083">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pillai</surname><given-names initials="G">Goonaseelan</given-names></name><xref ref-type="aff" rid="af3-cpaa-8-083">3</xref></contrib></contrib-group><aff id="af1-cpaa-8-083"><label>1</label>University of KwaZulu-Natal, Durban</aff><aff id="af2-cpaa-8-083"><label>2</label>Department of Internal Medicine, RK Khan Regional Hospital, Chatsworth, South Africa</aff><aff id="af3-cpaa-8-083"><label>3</label>Novartis Pharma AG, Basel, Switzerland</aff><author-notes><corresp id="c1-cpaa-8-083">Correspondence: Poobalan Naidoo, Department of Internal Medicine, RK Khan Regional Hospital, Chatsworth 4092, South Africa, Tel + 27 71 893 7672, Email <email>poobalan1naidoo@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>12</day><month>7</month><year>2016</year></pub-date><volume>8</volume><issue-id pub-id-type="pmc-issue-id">262547</issue-id><fpage>83</fpage><lpage>92</lpage><pub-history><event event-type="pmc-release"><date><day>12</day><month>07</month><year>2016</year></date></event><event event-type="pmc-live"><date><day>28</day><month>07</month><year>2016</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2016-07-30 20:52:37.340"><day>30</day><month>07</month><year>2016</year></date></event></pub-history><permissions><copyright-statement>&#169; 2016 Rambiritch et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2016</copyright-year><license><license-p>The full terms of this license are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#8211; Non Commercial (unported, v3.0) License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cpaa-8-083.pdf"/><abstract><sec><title>Aim</title><p>The aim of this study was to describe the pharmacokinetics (PK) of glibenclamide in poorly controlled South African type 2 diabetic subjects using noncompartmental and model-based methods.</p></sec><sec><title>Methods</title><p>A total of 24 subjects with type 2 diabetes were administered increasing doses (0 mg/d, 2.5 mg/d, 5 mg/d, 10 mg/d, and 20 mg/d) of glibenclamide daily at 2-week intervals. Plasma glibenclamide, glucose, and insulin determinations were performed. Blood sampling times were 0 minute, 30 minutes, 60 minutes, 90 minutes, and 120 minutes (post breakfast sampling) and 240 minutes, 270 minutes, 300 minutes, 330 minutes, 360 minutes, and 420 minutes (post lunch sampling) on days 14, 28, 42, 56, and 70 for doses of 0 mg, 2.5 mg, 5.0 mg, 10 mg, and 20 mg, respectively. Blood sampling was performed after the steady state was reached. A total of 24 individuals in the data set contributed to a total of 841 observation records. The PK was analyzed using noncompartmental analysis methods, which were implemented in WinNonLin<sup>&#174;</sup>, and population PK analysis using NONMEM<sup>&#174;</sup>. Glibenclamide concentration data were log transformed prior to fitting.</p></sec><sec><title>Results</title><p>A two-compartmental disposition model was selected after evaluating one-, two-, and three-compartmental models to describe the time course of glibenclamide plasma concentration data. The one-compartment model adequately described the data; however, the two-compartment model provided a better fit. The three-compartment model failed to achieve successful convergence. A more complex model, to account for enterohepatic recirculation that was observed in the data, was unsuccessful.</p></sec><sec><title>Conclusion</title><p>In South African diabetic subjects, glibenclamide demonstrates linear PK and was best described by a two-compartmental model. Except for the absorption rate constant, the other PK parameters reported in this study are comparable to those reported in the scientific literature. The study is limited by the small study sample size and inclusion of poorly controlled type 2 diabetic subjects.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>type 2 diabetes mellitus</kwd><kwd>glibenclamide</kwd><kwd>pharmacokinetics</kwd><kwd>compartmental</kwd><kwd>NONMEM model</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Pharmacometrics is the science that uses mathematics and statistics to characterize, understand, and predict a drug&#8217;s pharmacokinetic (PK) and pharmacodynamic behavior.<xref rid="b1-cpaa-8-083" ref-type="bibr">1</xref> Pharmacometrics is minimally present in South Africa.<xref rid="b2-cpaa-8-083" ref-type="bibr">2</xref> Population PK modeling, a component of pharmacometrics, assists with optimization of drug therapy.<xref rid="b3-cpaa-8-083" ref-type="bibr">3</xref> Historically, PK parameters are seldom investigated in South African subjects because of local limited pharmacometric resources. Specifically, the PK of glibenclamide, a second-generation sulfonylurea,<xref rid="b4-cpaa-8-083" ref-type="bibr">4</xref> have not been studied in South African subjects. The Society for Endocrinology, Metabolism, and Diabetes of South Africa currently attempts to phase out the use of glibenclamide because of its tendency to cause severe hypoglycemia, as well as the lack of renal function testing in a significant number of South Africans with diabetes.<xref rid="b5-cpaa-8-083" ref-type="bibr">5</xref> The maximum dose of glibenclamide in South Africa has been reduced since the drug was first introduced onto the market as supported by a dose&#8211;response study.<xref rid="b6-cpaa-8-083" ref-type="bibr">6</xref></p><p>Despite the limitations of glibenclamide, its ready availability, low cost, and indication for gestational diabetes<xref rid="b5-cpaa-8-083" ref-type="bibr">5</xref> will likely mean that it will be years before it is phased out.</p><p>The primary purpose of this analysis was to describe the population PK of glibenclamide in type 2 diabetic South African subjects, so that the estimated PK parameters can be used in the subsequent PK pharmacodynamic (PKPD) modeling to inform appropriate dose selection. In addition, we wanted to compare glibenclamide PK parameters between South African subjects and those reported in the literature.</p></sec><sec><title>Data used for population PK modeling</title><p>This clinical study was conducted in accordance with the Declaration of Helsinki and its amendments and the Patients&#8217; Rights Charter. The study was approved by the Biomedical Research Ethics Committee of the University of Durban-Westville. All patients provided written informed consent to participate, and the clinical study was previously published.<xref rid="b7-cpaa-8-083" ref-type="bibr">7</xref></p><p>Inclusion criteria were as follows: subjects with type 2 diabetes requiring oral antidiabetic therapy; age &gt;20 years; fasting blood glucose &gt;9 mmol/L despite oral antidiabetic therapy; and signed informed consent. Exclusion criteria were being on insulin therapy, allergy to sulfur, and any contraindications to multiple blood sampling, eg, poor venous access. Withdrawal criteria were retraction of consent, intolerance to glibenclamide (eg, allergy to sulfonamides during the study), blood glucose &lt;3.5 mmol/L, and signs or symptoms of hypoglycemia.</p><p>A total of 24 subjects with type 2 diabetes were administered increasing doses (0 mg/d, 2.5 mg/d, 5 mg/d, 10 mg/d, and 20 mg/d) of glibenclamide at 2-week intervals. Glibenclamide, glucose, and insulin determinations were performed. There were 24 individuals in the data set who contributed to a total of 841 observation records. Blood sampling times were 0 minute, 30 minutes, 60 minutes, and 90 minutes, 120 minutes (post breakfast sampling) and 240 minutes, 270 minutes, 300 minutes, 330 minutes, 360 minutes, and 420 minutes (post lunch sampling) on days 14, 28, 42, 56, and 70 for doses of 0 mg, 2.5 mg, 5.0 mg, 10 mg, and 20 mg, respectively. Blood sampling was performed after the steady state was reached.</p><p>Four subjects (subject numbers: 14, 16, 20, and 24) did not have complete data sets. In the case of subject 14, all ten samples at the dose of 2.5 mg and samples at time 0 hour and 0.5 hours at the dose of 5 mg were lost in transit between the clinical center and the analytical laboratory. Similarly, in subject 20, who completed all doses, ten samples at the dose of 10 mg were lost in transit.</p><p>Subject 16 could not proceed with dose escalation beyond 5 mg since blood glucose levels were 3.6 mmol/L after 7 hours. Therefore, there were no concentration versus time profile sets at doses of 10 mg and 20 mg.</p><p>Subject 24 absconded from the study after the dose of 2.5 mg. All attempts to contact him were unsuccessful.</p></sec><sec><title>Pharmacostatistical model development</title><p>Noncompartmental analysis (NCA), implemented in Win-NonLin<sup>&#174;</sup>, provided exploratory data for initial estimates and guides for population PK analysis. This analysis included all those subjects (n=22) who completed the full dose-escalation study and from whom sufficient data were available to characterize concentration versus time profiles.</p><p>The structural PK model selected was based on the NONMEM<sup>&#174;</sup> objective function (OF) value and diagnostic plots.</p><p>The structural PK model was implemented in NONMEM by selecting the appropriate ADVAN and TRANS subroutine from the PREDPP library of models. The first-order conditional estimation method with interaction was used throughout this analysis.</p><p>Unexplained intersubject variability in structural model parameters was estimated using the following model with the random effect <italic toggle="yes">&#951;<sub>j</sub></italic> (<xref ref-type="disp-formula" rid="fd1-cpaa-8-083">Equation 1</xref>).
<disp-formula id="fd1-cpaa-8-083"><mml:math id="mm1" overflow="scroll"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mtext>TVP</mml:mtext><mml:mo>*</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#951;</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><label>(1)</label></disp-formula>where TVP is the typical value of the PK parameter <italic toggle="yes">Pv</italic> (eg, CL/f) in the population, <italic toggle="yes">P<sub>j</sub></italic> is the individual value for <italic toggle="yes">P</italic> in the <italic toggle="yes">j</italic>th individual, and <italic toggle="yes">&#951;<sub>j</sub></italic> is a random variable with mean of zero and variance <italic toggle="yes">&#969;P</italic><sup>2</sup>. This model assumes a log-normal distribution for the <italic toggle="yes">P<sub>j</sub></italic> values. Estimates of intersubject variability in <italic toggle="yes">P</italic> are presented as the square root of <italic toggle="yes">&#969;P</italic><sup>2</sup>, which is an approximation of the coefficient of variation (CV) of <italic toggle="yes">P</italic> for a log-normally distributed quantity.</p><p>The glibenclamide concentration data were log transformed prior to fitting. The residual error model of this log-transformed data consisted of an additive model as shown in <xref ref-type="disp-formula" rid="fd2-cpaa-8-083">Equation 2</xref>.
<disp-formula id="fd2-cpaa-8-083"><mml:math id="mm2" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>C</mml:mi><mml:mo>*</mml:mo><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><label>(2)</label></disp-formula>where <italic toggle="yes">C<sub>ij</sub></italic> is the <italic toggle="yes">i</italic>th concentration measured at time <italic toggle="yes">t<sub>i</sub></italic> in the <italic toggle="yes">j</italic>th individual. <italic toggle="yes">C</italic>*<italic toggle="yes">ij</italic> is the respective model-predicted concentration and the <italic toggle="yes">&#949;<sub>ij</sub></italic> is a normally distributed error term with mean of zero and variances. Examples of potential sources of residual variability (depicted as <italic toggle="yes">&#949;<sub>ij</sub></italic> in <xref ref-type="disp-formula" rid="fd2-cpaa-8-083">Equation 2</xref>) include assay error, deviations from the model specification, and intrasubject variability.</p></sec><sec sec-type="results"><title>Results</title><p>A summary of the baseline characteristics of the study cohort is given in <xref ref-type="table" rid="t1-cpaa-8-083">Table 1</xref>.</p><p>NCA showed that there is a linearity between area under the curve (AUC) (AUC<sub>last</sub> and AUC<sub>inf</sub>) of glibenclamide with increasing doses. The corresponding values of <italic toggle="yes">C</italic><sub>max</sub> also increased linearly. The <italic toggle="yes">T</italic><sub>max</sub> ranged from 1.62 hours to 2.09 hours. Clearance (CL/f) ranges from 1.94 L/h to 3.09 L/h, while the half-life ranges from 4.42 hours to 8.08 hours. The volume of distribution (<italic toggle="yes">V</italic><sub>z</sub>/f) ranges from 14.63 L to 32.48 L. Noncompartmental PK parameters for glibenclamide are presented in <xref ref-type="table" rid="t2-cpaa-8-083">Table 2</xref>.</p><p>A two-compartmental disposition model (<xref ref-type="fig" rid="f1-cpaa-8-083">Figure 1</xref>) was selected after evaluating one-, two-, and three-compartmental models to describe the time course of glibenclamide plasma concentration data. The three-compartment model failed to achieve successful convergence as the intercompartmental transfer rates went to infinity suggesting that the third compartment was poorly identified.</p><p>As depicted in the model diagnostic plots (<xref ref-type="fig" rid="f2-cpaa-8-083">Figures 2</xref> and <xref ref-type="fig" rid="f3-cpaa-8-083">3</xref>), the one-compartment model gives an adequate description of the data; however, the two-compartment model provided a better fit as judged by a drop in OF value of 188 (&#8722;243 versus &#8722;431). All attempts to model observed enterohepatic recirculation were unsuccessful. Visual inspection of <xref ref-type="fig" rid="f4-cpaa-8-083">Figure 4</xref> indicates that subjects 4, 7, 9, 10, and 14 all showed potential enterohepatic recycling (EHC) of drug at 20 mg and subjects 4, 9, and 10 at 10 mg of glibenclamide. The EHC of glibenclamide was not therefore captured in a pharmacokinetic model since the majority of subjects (19) did not show EHC, and also because there were not enough data points to fully characterize the EHC profile.</p><p>The final model was subjected to a posterior predictive check (PPC).<xref rid="b8-cpaa-8-083" ref-type="bibr">8</xref> In this procedure, 500 replications were run using the fixed and random effects from the final population PK model and using a study design identical to that used in this study. The median AUC for each dose from each replicate was calculated, and the distribution of AUC values was compared with the median for each dose level calculated using NCA methods. <xref ref-type="fig" rid="f5-cpaa-8-083">Figure 5</xref> shows that the observed (NCA) median AUC falls within the distribution of simulated AUC values confirming the good predictive ability of the model.</p><p>The PK parameters of glibenclamide from the one-compartment and the final two-compartment models are presented in <xref ref-type="table" rid="t3-cpaa-8-083">Table 3</xref>. Individual PK parameters, obtained from the two-compartment model, are presented in <xref ref-type="table" rid="t4-cpaa-8-083">Table 4</xref>. The PK of glibenclamide is linear after multiple-dose administration in the dose range of 2.5&#8211;20 mg as suggested by the model diagnostic boxplots of population PK parameters versus dose (<xref ref-type="fig" rid="f6-cpaa-8-083">Figure 6</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>PK parameters derived from NCA</title><p>This discussion provides a comparison of results obtained from NCA in this study to that reported in the literature. The NCA analysis also provided initial estimates and guided the population PK analysis.</p><p>The &#8220;clearance&#8221; of glibenclamide in this study population ranges from 1.94 L/h to 3.09 L/h. The mean age of this population is 54.1 years, ranging from 39 years to 73 years. The mean creatinine of the study population is 64.1 &#956;mol/L, which is within the normal range, and therefore it is assumed to have normal renal function. The clearance of glibenclamide in this study population is within the range reported by other researchers who investigated type 2 diabetics with normal renal function and of the same age group: Jaber et al,<xref rid="b9-cpaa-8-083" ref-type="bibr">9</xref> 3.2 L/h; J&#246;nsson et al,<xref rid="b10-cpaa-8-083" ref-type="bibr">10</xref> 4.41 L/h (Caucasians) and 4.1 L/h (Chinese); and J&#246;nsson et al,<xref rid="b11-cpaa-8-083" ref-type="bibr">11</xref> 3.7 L/h.</p><p>The apparent volume of distribution (<italic toggle="yes">V</italic><sub>z</sub>/f) of this study population ranged from 14.63 L to 32.48 L and is consistent with the literature. Jaber et al<xref rid="b9-cpaa-8-083" ref-type="bibr">9</xref> reported values of 20 L, 41 L, and 51 L, after 0 week, 6 weeks, and 12 weeks, respectively, of glibenclamide therapy. J&#246;nsson et al<xref rid="b10-cpaa-8-083" ref-type="bibr">10</xref> in his comparison of Caucasian and Chinese subjects reported values of 6.31 L and 5.49 L, respectively.</p><p>The &#8220;half-life&#8221; (<italic toggle="yes">t</italic><sub>1/2</sub>) of glibenclamide in this study ranged from 4.42 hours to 8.08 hours. Marble et al<xref rid="b12-cpaa-8-083" ref-type="bibr">12</xref> and White and Keith Cambell<xref rid="b13-cpaa-8-083" ref-type="bibr">13</xref> reported half-lives of 6&#8211;10 hours. This half-life is within the range as reported for type 2 diabetic patients (the half-life for micronized glibenclamide ranged from 2.1 hours<xref rid="b14-cpaa-8-083" ref-type="bibr">14</xref> to 8.3 hours).<xref rid="b15-cpaa-8-083" ref-type="bibr">15</xref> Jaber et al<xref rid="b8-cpaa-8-083" ref-type="bibr">8</xref> reported a half-life of 12.2 hours, J&#246;nsson et al<xref rid="b16-cpaa-8-083" ref-type="bibr">16</xref> 7.09 hours, and J&#246;nsson et al<xref rid="b10-cpaa-8-083" ref-type="bibr">10</xref> 2.0&#8211;4.5 hours for Caucasian and Chinese. Courtois et al<xref rid="b17-cpaa-8-083" ref-type="bibr">17</xref> reported half-lives of 2.63 hours (42&#8211;59 years) and 2.78 hours (71&#8211;75 years).</p><p>There is a linear increase in the maximum glibenclamide blood concentration (<italic toggle="yes">C</italic><sub>max</sub>) as the dose of glibenclamide is increased from 2.5 mg to 20 mg, that is, 157.97 ng/mL to 773.61 ng/mL, respectively.</p><p><italic toggle="yes">C</italic><sub>max</sub> reported in this study is approximately twice that reported for corresponding doses by other researchers, namely, for the dose of 5 mg, Fleishaker and Phillips<xref rid="b15-cpaa-8-083" ref-type="bibr">15</xref> reported a <italic toggle="yes">C</italic><sub>max</sub> of 179 ng/mL and Coppack et al<xref rid="b14-cpaa-8-083" ref-type="bibr">14</xref> reported a <italic toggle="yes">C</italic><sub>max</sub> of 241 ng/mL and 354 ng/mL for 10 mg (fasting) and 20 mg (fasting) of glibenclamide, respectively, while Jaber et al<xref rid="b8-cpaa-8-083" ref-type="bibr">8</xref> reported a <italic toggle="yes">C</italic><sub>max</sub> of 278 ng/mL for 2.5 mg (in solution) of glibenclamide in solution and J&#246;nsson et al<xref rid="b10-cpaa-8-083" ref-type="bibr">10</xref> reported a low max of 69 ng/mL (Caucasians) and 82 ng/mL (Chinese) for 2.5 mg of glibenclamide. However, when 1.25 mg of glibenclamide was given intravenously, the <italic toggle="yes">C</italic><sub>max</sub> was appreciably higher (376 ng/mL [Caucasian] and 368 ng/mL [Chinese]].<xref rid="b10-cpaa-8-083" ref-type="bibr">10</xref> This wide variation in <italic toggle="yes">C</italic><sub>max</sub> is indicative of the variable bioavailability of glibenclamide. This is confirmed by the very high <italic toggle="yes">C</italic><sub>max</sub> obtained by J&#246;nsson et al.<xref rid="b11-cpaa-8-083" ref-type="bibr">11</xref></p><p>The time taken to reach <italic toggle="yes">C</italic><sub>max</sub> (<italic toggle="yes">T</italic><sub>max</sub>) of 1.62&#8211;2.09 hours is comparable to the values reported in the literature.<xref rid="b8-cpaa-8-083" ref-type="bibr">8</xref>,<xref rid="b10-cpaa-8-083" ref-type="bibr">10</xref>,<xref rid="b11-cpaa-8-083" ref-type="bibr">11</xref>,<xref rid="b14-cpaa-8-083" ref-type="bibr">14</xref>,<xref rid="b16-cpaa-8-083" ref-type="bibr">16</xref>,<xref rid="b17-cpaa-8-083" ref-type="bibr">17</xref> However, as shown in this study, there is no coincidence in the <italic toggle="yes">T</italic><sub>max</sub> of glibenclamide, glucose, and insulin.</p></sec><sec><title>Population PK model selection</title><p>Three population PK models were fitted to the glibenclamide PK data using nonlinear mixed effects modeling. While both the one- and two-compartment models terminated successfully, and produced similar graphical model diagnostic plots, the two-compartment model provided a better comparative fit due to its significantly lower OF (&#8722;243.409 versus &#8722;431.164). A three-compartment model was also attempted but was considered over parameterized as the model failed to achieve successful convergence due to the intercompartment transfer rate constants being estimated as infinite. This suggested that the third compartment was poorly defined.</p><p>Despite extensive attempts at model refinement, the EHC model did not converge successfully. This is possibly due to a wide between-subject variability as well as within-subject variability in EHC, ie, some subjects show evidence of EHC at some doses but not at other dose levels. Furthermore, there were not enough data points to fully characterize the EHC profile in all subjects. This model was eventually abandoned, and the two-compartment model was accepted as the final model. It was acknowledged that the poorly fitted EHC component of the profile in the final model would contribute to an inflated residual variability due to model misspecification. Despite this drawback, however, the two-compartment model provided a good fit of the model to the data as confirmed by the PPC. In particular, the model was able to provide an estimate of exposure (AUC) to glibenclamide that was consistent with the NCA estimates. This was important since one use of the PK model was to provide an estimate of average glibenclamide concentration (<italic toggle="yes">C</italic><sub>pss</sub>) for use as the driving force in a PKPD model. PPC is a method for the objective assessment of the predictive ability of a model and is a robust method for model evaluation. Yano et al<xref rid="b8-cpaa-8-083" ref-type="bibr">8</xref> concluded that &#8220;if a PPC invalidates a model, one can be reasonably certain that the model has serious deficiencies.&#8221;</p><p>The low relative standard error (SE) indicated the good precision of the estimated parameters and the anticipated relatively high residual variability was also noted (43.5% CV). The residual variability consists of assay error, deviations from the model specification, and intrasubject variability. In the final two-compartment model selected, one source of model misspecification is the inability to characterize the EHC of glibenclamide that was noted in several subjects. In addition, in some subjects, the predose glibenclamide concentration was also not well fitted by the model. This might reflect the lower degree of confidence in the dosing history (compliance with regard to timing and size of dose or even administration) for the unsupervised doses that contribute to the predose concentration.</p><p>Individual plots of the glibenclamide concentration versus time profiles from the final two-compartment model show a very close agreement between the observed and model predictions. The relatively low between-subject variability in clearance (&#8764;34% CV) and apparent volume of distribution (&#8764;23% CV) suggested that covariates might not significantly improve the population fit. In addition, graphical examination of the PK parameters versus covariates did not reveal any obvious relationships. Consequently, no formal covariate analysis was conducted.</p><sec><title>Population PK parameters</title><p>The PK parameters derived from the two-compartment model are discussed in relation to published data.</p><p>Glibenclamide is completely absorbed after oral administration, and the rate and extent of absorption are not affected by food.<xref rid="b8-cpaa-8-083" ref-type="bibr">8</xref> Therefore, estimates for clearance and volume of distribution after oral administration are considered to be close approximations of those after intravenous administration. In this study, the dose of glibenclamide was taken on an empty stomach, 10 minutes before breakfast.</p><p>Using a one-compartment model, the <italic toggle="yes">V</italic><sub>d</sub> was 38.90 L (0.55 L/kg), which approximates that reported by Tracewell et al<xref rid="b18-cpaa-8-083" ref-type="bibr">18</xref> (43.7 L; 0.509 L/kg) in their study of glibenclamide PK using a one-compartment model with first-order absorption and first-order elimination. Other studies quoted by Tracewell et al<xref rid="b18-cpaa-8-083" ref-type="bibr">18</xref> report <italic toggle="yes">V</italic><sub>d</sub> values of 0.735&#177;0.0150 L/kg, 0.19&#177;0.01 L/kg, 0.125&#177;0.008 L/kg, 0.017&#177;0.00714 L/kg, 0.200&#177;0.032 L/kg, 0.144&#177;0.0156 L/kg, 0.0413&#177;0.000975 L/kg, and 0.57&#177;0.57 L/kg. Jaber et al<xref rid="b8-cpaa-8-083" ref-type="bibr">8</xref> reported a <italic toggle="yes">V</italic><sub>d</sub> of 51&#177;51 L/h using a one-compartment model after a 12-week study. The <italic toggle="yes">V</italic><sub>d</sub> of this population is within the range reported in the literature.</p><p>The volume of distribution &#177; SE of glibenclamide for the two-compartment model is 11.70&#177;1.11 L and 68.1&#177;6.0 L for the central and peripheral compartments, respectively. This difference may be due to the separation of the compartments during modeling.</p><p>The average clearance for glibenclamide is 1.52&#177;0.12 L/h (0.02 L/h/kg) for the one-compartment model and 2.16&#177;0.16 for the two-compartment model. The intercompartmental clearance (Q/f) is 3.84&#177;0.58 L/h. Tracewell et al<xref rid="b18-cpaa-8-083" ref-type="bibr">18</xref> reported average values for glibenclamide clearance of 0.0387&#177;0.00642 L/h/kg in younger diabetics (&lt;60 years) and 0.0525&#177;0.00349 L/h/kg in older subjects (&gt;60 years). Other studies quoted by Trace-well et al<xref rid="b18-cpaa-8-083" ref-type="bibr">18</xref> reported clearance values of 0.107&#177;0.051 L/h/kg, 0.078&#177;0.00516 L/h/kg, 0.0634&#177;0.00803 L/h/kg, 0.09&#177;0.03 L/h/kg, 0.078&#177;0.029 L/h/kg, and 0.0394&#177;0.00891 L/h/kg. In addition, Jaber et al,<xref rid="b9-cpaa-8-083" ref-type="bibr">9</xref> J&#246;nsson et al,<xref rid="b16-cpaa-8-083" ref-type="bibr">16</xref> and J&#246;nsson et al,<xref rid="b11-cpaa-8-083" ref-type="bibr">11</xref> reported clearance values &#177;SE of 3.2&#177;2.1, 4.41 L/h (range 3.38&#8211;8.11 for Caucasians) and 4.10 L/h (range 2.91&#8211;5.98 for Chinese); and 3.70 L/h (1.15), respectively. The clearance value obtained for this study (mean age: 54.1&#177;9.2 years) falls within the range of other reported studies and that of Tracewell et al<xref rid="b18-cpaa-8-083" ref-type="bibr">18</xref> for their study population aged &lt;60 years.</p><p>The average Ka (&#177;SE) is 2.39&#177;0.34 h<sup>&#8722;1</sup> (one-compartment model) and 0.53&#177;0.04 h<sup>&#8722;1</sup> (two-compartment model). J&#246;nsson et al,<xref rid="b11-cpaa-8-083" ref-type="bibr">11</xref> Ryderberg et al,<xref rid="b19-cpaa-8-083" ref-type="bibr">19</xref> and Tracewell et al<xref rid="b18-cpaa-8-083" ref-type="bibr">18</xref> reported Ka values of 2.68&#177;1.50 h<sup>&#8722;1</sup>, 0.756 h<sup>&#8722;1</sup>, and 0.057&#177;0.244 h<sup>&#8722;1</sup>, respectively. Reppas<xref rid="b20-cpaa-8-083" ref-type="bibr">20</xref> reported that the variation in Ka values may be due to kinetic sensitivity, linearity, specificity, and precision.</p><p>Furthermore, the sampling interval in the absorptive phase coupled with variations in physiological factors may also contribute to this wide variation.</p><p>Limitations of this study include the small study sample and inclusion of poorly controlled type 2 diabetic patients. Extrapolation of the study findings to the greater population must be performed with caution. Nevertheless, the study does serve as a starting point to understand the PK of glibenclamide in type 2 diabetic subjects, which has not been previously reported.</p></sec></sec></sec><sec><title>Conclusion</title><p>PK results obtained from NCA did not differ in any marked way from those obtained from the mixed effects modeling (NONMEM) results. The PK parameters of glibenclamide obtained from the NCA are consistent with those obtained from the literature. The PK of glibenclamide in this study population was described by a two-compartmental disposition model with first-order absorption. The PK of glibenclamide in this study population is comparable to that reported in the literature, save for the absorption rate constant. The model was subjected to internal validation using the PPC approach and provided acceptable model predictions. The study is limited by the small sample size and inclusion of poorly controlled type 2 diabetic patients.</p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>G Pillai has stocks in Novartis. The other authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-cpaa-8-083"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Ette</surname><given-names>EI</given-names></name><name name-style="western"><surname>Williams</surname><given-names>PJ</given-names></name></person-group><source>Pharmacometrics: The Science of Quantitative Pharmacology</source><publisher-loc>Hoboken NJ</publisher-loc><publisher-name>John Wiley and Sons, Inc</publisher-name><year>2007</year></element-citation></ref><ref id="b2-cpaa-8-083"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pillai</surname><given-names>G</given-names></name><name name-style="western"><surname>Davies</surname><given-names>G</given-names></name><name name-style="western"><surname>Denti</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2013</year><volume>28</volume><issue>2</issue><fpage>e69</fpage><pub-id pub-id-type="pmid">23985967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/psp.2013.45</pub-id><pub-id pub-id-type="pmcid">PMC3828009</pub-id></element-citation></ref><ref id="b3-cpaa-8-083"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>AM</given-names></name></person-group><article-title>Recent advances in pharmacokinetic modeling</article-title><source>Biopharm Drug Dispos</source><year>2007</year><volume>28</volume><issue>3</issue><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">17295411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bdd.540</pub-id></element-citation></ref><ref id="b4-cpaa-8-083"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>JM</given-names></name></person-group><article-title>Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects</article-title><source>Pharmacotherapy</source><year>1985</year><volume>5</volume><issue>2</issue><fpage>43</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">3923453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1875-9114.1985.tb03404.x</pub-id></element-citation></ref><ref id="b5-cpaa-8-083"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amod</surname><given-names>A</given-names></name><name name-style="western"><surname>Ascott-Evans</surname><given-names>BH</given-names></name><name name-style="western"><surname>Berg</surname><given-names>GI</given-names></name><etal/><collab>Guideline Committee</collab></person-group><article-title>The 2012 SEMDSA guideline for the management of type 2 diabetes (revised)</article-title><source>JEMDSA</source><year>2012</year><volume>17</volume><issue>2</issue><fpage>S1</fpage><lpage>S95</lpage><comment>Supplement 1</comment></element-citation></ref><ref id="b6-cpaa-8-083"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rambiritch</surname><given-names>V</given-names></name><name name-style="western"><surname>Naidoo</surname><given-names>P</given-names></name><name name-style="western"><surname>Butkow</surname><given-names>N</given-names></name></person-group><article-title>Dose-response relationships of sulfonylureas: will doubling the dose double the response?</article-title><source>South Med J</source><year>2007</year><volume>100</volume><issue>11</issue><fpage>1132</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">17984746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SMJ.0b013e318158420f</pub-id></element-citation></ref><ref id="b7-cpaa-8-083"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rambiritch</surname><given-names>V</given-names></name><name name-style="western"><surname>Maharaj</surname><given-names>B</given-names></name><name name-style="western"><surname>Naidoo</surname><given-names>P</given-names></name></person-group><article-title>Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study</article-title><source>Clin Pharmacol</source><year>2014</year><volume>4</volume><issue>6</issue><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">24741335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CPAA.S54809</pub-id><pub-id pub-id-type="pmcid">PMC3983009</pub-id></element-citation></ref><ref id="b8-cpaa-8-083"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yano</surname><given-names>Y</given-names></name><name name-style="western"><surname>Beal</surname><given-names>SL</given-names></name><name name-style="western"><surname>Sheiner</surname><given-names>LB</given-names></name></person-group><article-title>Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check</article-title><source>J Pharmacokinet Pharmacodyn</source><year>2001</year><volume>28</volume><issue>2</issue><fpage>171</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">11381569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1011555016423</pub-id></element-citation></ref><ref id="b9-cpaa-8-083"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaber</surname><given-names>LA</given-names></name><name name-style="western"><surname>Antal</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Slaughter</surname><given-names>RL</given-names></name><name name-style="western"><surname>Welshman</surname><given-names>IR</given-names></name></person-group><article-title>Comparison of pharmacokinetics and pharmacodynamics of short and long-term glyburide therapy in NIDDM</article-title><source>Diabetes Care</source><year>1994</year><volume>17</volume><issue>11</issue><fpage>1300</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">7821171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diacare.17.11.1300</pub-id></element-citation></ref><ref id="b10-cpaa-8-083"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#246;nsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Chan</surname><given-names>JC</given-names></name><name name-style="western"><surname>Rydberg</surname><given-names>T</given-names></name><etal/></person-group><article-title>Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes</article-title><source>Eur J Clin Pharmacol</source><year>2000</year><volume>55</volume><issue>10</issue><fpage>721</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">10663449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280050004</pub-id></element-citation></ref><ref id="b11-cpaa-8-083"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#246;nsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Rydberg</surname><given-names>T</given-names></name><name name-style="western"><surname>Sterner</surname><given-names>G</given-names></name><name name-style="western"><surname>Melander</surname><given-names>A</given-names></name></person-group><article-title>Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function</article-title><source>Eur J Clin Phamacol</source><year>1998</year><volume>53</volume><issue>6</issue><fpage>429</fpage><lpage>435</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280050403</pub-id><pub-id pub-id-type="pmid">9551701</pub-id></element-citation></ref><ref id="b12-cpaa-8-083"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Marble</surname><given-names>A</given-names></name><name name-style="western"><surname>Weir</surname><given-names>GC</given-names></name><name name-style="western"><surname>Selenkow</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Endocrine diseases</article-title><person-group person-group-type="editor"><name name-style="western"><surname>Speight</surname><given-names>TM</given-names></name></person-group><source>Avery&#8217;s Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics</source><edition>3rd ed</edition><publisher-loc>Auckland</publisher-loc><publisher-name>Adis</publisher-name><year>1987</year><fpage>522</fpage><lpage>590</lpage></element-citation></ref><ref id="b13-cpaa-8-083"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>JR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Keith Cambell</surname><given-names>R</given-names></name></person-group><article-title>Diabetes mellitus</article-title><person-group person-group-type="editor"><name name-style="western"><surname>Herfindal</surname><given-names>ET</given-names></name><name name-style="western"><surname>Gourley</surname><given-names>DR</given-names></name></person-group><source>Textbook of Therapeutics, Drug and Disease Management</source><edition>6th ed</edition><publisher-loc>Philadelphia, USA</publisher-loc><publisher-name>Williams and Wilkins</publisher-name><year>1996</year><fpage>357</fpage><lpage>386</lpage></element-citation></ref><ref id="b14-cpaa-8-083"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coppack</surname><given-names>SW</given-names></name><name name-style="western"><surname>Lant</surname><given-names>AF</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>CS</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>AV</given-names></name></person-group><article-title>Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus</article-title><source>Br J Clin Pharmacol</source><year>1990</year><volume>29</volume><issue>6</issue><fpage>637</fpage><lpage>684</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1990.tb03688.x</pub-id><pub-id pub-id-type="pmcid">PMC1380169</pub-id><pub-id pub-id-type="pmid">2116159</pub-id></element-citation></ref><ref id="b15-cpaa-8-083"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleishaker</surname><given-names>JC</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>JP</given-names></name></person-group><article-title>Evaluation of a potential interaction between erythromycin and glyburide in diabetic volunteers</article-title><source>J Clin Pharmacol</source><year>1991</year><volume>31</volume><issue>3</issue><fpage>259</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">1902238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.1991.tb04972.x</pub-id></element-citation></ref><ref id="b16-cpaa-8-083"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#246;nsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Chan</surname><given-names>JC</given-names></name><name name-style="western"><surname>Rydberg</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes</article-title><source>Eur J Clin Pharmacol</source><year>2000</year><volume>56</volume><issue>9&#8211;10</issue><fpage>711</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">11214781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280000214</pub-id></element-citation></ref><ref id="b17-cpaa-8-083"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courtois</surname><given-names>P</given-names></name><name name-style="western"><surname>Sener</surname><given-names>A</given-names></name><name name-style="western"><surname>Herbaut</surname><given-names>C</given-names></name><name name-style="western"><surname>Turc</surname><given-names>A</given-names></name><name name-style="western"><surname>Malaisse</surname><given-names>WJ</given-names></name></person-group><article-title>Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects</article-title><source>Res Commun Mol Pathol Pharmacol</source><year>1999</year><volume>103</volume><issue>2</issue><fpage>211</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">10461687</pub-id></element-citation></ref><ref id="b18-cpaa-8-083"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tracewell</surname><given-names>WG</given-names></name><name name-style="western"><surname>Stalker</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Maloley</surname><given-names>PA</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>TE</given-names></name><name name-style="western"><surname>Gwilt</surname><given-names>PR</given-names></name></person-group><article-title>Population pharmacokinetics of glyburide in patients with well controlled diabetes</article-title><source>Pharmacotherapy</source><year>1998</year><volume>18</volume><issue>1</issue><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">9469681</pub-id></element-citation></ref><ref id="b19-cpaa-8-083"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rydberg</surname><given-names>T</given-names></name><name name-style="western"><surname>J&#246;nsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name><name name-style="western"><surname>Melander</surname><given-names>A</given-names></name></person-group><article-title>Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics</article-title><source>Br J Clin Pharmacol</source><year>1997</year><volume>43</volume><issue>4</issue><fpage>373</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">9146849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.1997.00571.x</pub-id><pub-id pub-id-type="pmcid">PMC2042760</pub-id></element-citation></ref><ref id="b20-cpaa-8-083"><label>20</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Reppas</surname><given-names>C</given-names></name></person-group><comment>webpage on the Internet</comment><source>The Assessment of the Absorption Rate in Bioequivalence Studies: What Do We Really Want to Know? Third European Intensive Course on New Forms and New Routes of Administration for Drugs</source><year>1997</year><comment>Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://old.unipr.it/arpa/dipfarm/news/newstill2000/erasmus/erasm3.html">http://old.unipr.it/arpa/dipfarm/news/newstill2000/erasmus/erasm3.html</ext-link></comment><date-in-citation>Accessed June 22, 2015</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig id="f1-cpaa-8-083" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Schematic representation of two-compartmental PK model and model equations.</p><p><bold>Notes:</bold> Ka, absorption rate constant; K12/K21, intercompartment transfer constants; V1, volume of central compartment; V2, volume of peripheral compartment.</p><p><bold>Abbreviations:</bold> CL, clearance; PK, pharmacokinetic.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cpaa-8-083Fig1.jpg"/></fig><fig id="f2-cpaa-8-083" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Model diagnostics: observed versus model predicted concentrations for the one-compartment model shown as points in the graph.</p><p><bold>Note:</bold> The solid line represents the line of identity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cpaa-8-083Fig2.jpg"/></fig><fig id="f3-cpaa-8-083" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Model diagnostics: observed versus model predicted concentrations from the final two-compartment model shown as points in the graph.</p><p><bold>Note:</bold> The solid line represents the line of identity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cpaa-8-083Fig3.jpg"/></fig><fig id="f4-cpaa-8-083" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Plots of observed log glibenclamide concentrations (open circles), population model predictions (dotted line), and individual model predictions (solid line) from the final two-compartment model.</p><p><bold>Notes:</bold> Each row in the plot represents data for a single subject while each column represents data from a specific dose level. Blank cells indicate the subjects who did not receive that particular dose.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cpaa-8-083Fig4.jpg"/></fig><fig id="f5-cpaa-8-083" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Posterior predictive check of final two-compartment model.</p><p><bold>Notes:</bold> Bars show the distribution of simulated median AUC calculated from 500 replications of a dose-escalation PK study with 24 subjects (design identical to current study). The dashed vertical line shows the median AUC observed in the current study.</p><p><bold>Abbreviations:</bold> AUC, area under the curve; PK, pharmacokinetic.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cpaa-8-083Fig5.jpg"/></fig><fig id="f6-cpaa-8-083" position="float" orientation="portrait"><label>Figure 6</label><caption><p>Model diagnostics: boxplots of population PK parameters versus dose.</p><p><bold>Notes:</bold> The clear horizontal bar in the center of the box shows the median; the box encloses the interquartile range, ie, 50% of the data. The whiskers show the interval of values outside the box and values far outside are represented by horizontal dashes. Ka, absorption rate constant; V2, apparent volume of distribution for two-compartment model; V3, apparent volume of distribution for three-compartment model.</p><p><bold>Abbreviations:</bold> CL, clearance; PK, pharmacokinetic; h, hours.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cpaa-8-083Fig6.jpg"/></fig><table-wrap id="t1-cpaa-8-083" position="float" orientation="portrait"><label>Table 1</label><caption><p>Cohort characteristics at entry into the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">Normal range (where applicable)</th><th valign="top" align="left" rowspan="1" colspan="1">Mean</th><th valign="top" align="left" rowspan="1" colspan="1">&#177;SD</th><th valign="top" align="left" rowspan="1" colspan="1">Minimum</th><th valign="top" align="left" rowspan="1" colspan="1">Maximum</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">54</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">73</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Weight (kg)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">71.1</td><td valign="top" align="left" rowspan="1" colspan="1">14.1</td><td valign="top" align="left" rowspan="1" colspan="1">42.0</td><td valign="top" align="left" rowspan="1" colspan="1">107.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Height (cm)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">156</td><td valign="top" align="left" rowspan="1" colspan="1">9.0</td><td valign="top" align="left" rowspan="1" colspan="1">145</td><td valign="top" align="left" rowspan="1" colspan="1">173</td></tr><tr><td colspan="6" valign="top" align="left" rowspan="1">BMI (kg/m<sup>2</sup>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Males (n=2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">26.48</td><td valign="top" align="left" rowspan="1" colspan="1">5.64</td><td valign="top" align="left" rowspan="1" colspan="1">22.49</td><td valign="top" align="left" rowspan="1" colspan="1">30.46</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Females (n=20)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">29.93</td><td valign="top" align="left" rowspan="1" colspan="1">6.71</td><td valign="top" align="left" rowspan="1" colspan="1">19.05</td><td valign="top" align="left" rowspan="1" colspan="1">46.88</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fasting blood glucose (mmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">8.7&#8211;9.6</td><td valign="top" align="left" rowspan="1" colspan="1">15.4</td><td valign="top" align="left" rowspan="1" colspan="1">3.8</td><td valign="top" align="left" rowspan="1" colspan="1">9.9</td><td valign="top" align="left" rowspan="1" colspan="1">21.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fasting blood insulin (&#956;U/mL)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">13.9</td><td valign="top" align="left" rowspan="1" colspan="1">6.9</td><td valign="top" align="left" rowspan="1" colspan="1">3.0</td><td valign="top" align="left" rowspan="1" colspan="1">24.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Glycosylated hemoglobin (%)</td><td valign="top" align="left" rowspan="1" colspan="1">4.8&#8211;6.0</td><td valign="top" align="left" rowspan="1" colspan="1">12.2</td><td valign="top" align="left" rowspan="1" colspan="1">3.8</td><td valign="top" align="left" rowspan="1" colspan="1">8.1</td><td valign="top" align="left" rowspan="1" colspan="1">18.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cholesterol (mmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">3.6&#8211;5.1</td><td valign="top" align="left" rowspan="1" colspan="1">5.8</td><td valign="top" align="left" rowspan="1" colspan="1">1.2</td><td valign="top" align="left" rowspan="1" colspan="1">4.0</td><td valign="top" align="left" rowspan="1" colspan="1">8.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Low-density lipoprotein cholesterol (mmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8804;3.90</td><td valign="top" align="left" rowspan="1" colspan="1">3.9</td><td valign="top" align="left" rowspan="1" colspan="1">1.0</td><td valign="top" align="left" rowspan="1" colspan="1">2.2</td><td valign="top" align="left" rowspan="1" colspan="1">5.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">High-density lipoprotein cholesterol (mmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8805;1.42 (males)<break/>&#8805;1.68 (females)</td><td valign="top" align="left" rowspan="1" colspan="1">1.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.8</td><td valign="top" align="left" rowspan="1" colspan="1">1.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Triglycerides (mmol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">0.39&#8211;1.84</td><td valign="top" align="left" rowspan="1" colspan="1">1.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.5</td><td valign="top" align="left" rowspan="1" colspan="1">4.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Alanine transferase (U/L)</td><td valign="top" align="left" rowspan="1" colspan="1">10&#8211;60</td><td valign="top" align="left" rowspan="1" colspan="1">25.0</td><td valign="top" align="left" rowspan="1" colspan="1">12.6</td><td valign="top" align="left" rowspan="1" colspan="1">10.0</td><td valign="top" align="left" rowspan="1" colspan="1">59.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Creatinine (&#956;mol/L)</td><td valign="top" align="left" rowspan="1" colspan="1">64&#8211;112</td><td valign="top" align="left" rowspan="1" colspan="1">64.1</td><td valign="top" align="left" rowspan="1" colspan="1">10.4</td><td valign="top" align="left" rowspan="1" colspan="1">48.0</td><td valign="top" align="left" rowspan="1" colspan="1">91.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of diabetes (years)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0&#8211;5</td><td valign="top" align="left" rowspan="1" colspan="1">n=8</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">6&#8211;10</td><td valign="top" align="left" rowspan="1" colspan="1">n=6</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&gt;10</td><td valign="top" align="left" rowspan="1" colspan="1">n=8</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-cpaa-8-083"><p><bold>Abbreviation:</bold> BMI, body mass index.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-cpaa-8-083" position="float" orientation="portrait"><label>Table 2</label><caption><p>Noncompartmental PK metric (parameters) for glibenclamide</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Pharmacokinetic Metric</th><th valign="top" align="left" rowspan="1" colspan="1">Dose (mg)</th><th valign="top" align="left" rowspan="1" colspan="1">N</th><th valign="top" align="left" rowspan="1" colspan="1">Mean</th><th valign="top" align="left" rowspan="1" colspan="1">SD</th><th valign="top" align="left" rowspan="1" colspan="1">Median</th><th valign="top" align="left" rowspan="1" colspan="1">Minimum</th><th valign="top" align="left" rowspan="1" colspan="1">Maximum</th><th valign="top" align="left" rowspan="1" colspan="1">CV%</th></tr></thead><tbody><tr><td rowspan="4" valign="top" align="left" colspan="1">AUC<sub>inf</sub> (ng&#183;h/mL)</td><td valign="top" align="left" rowspan="1" colspan="1">2.5</td><td valign="top" align="left" rowspan="1" colspan="1">20.00</td><td valign="top" align="left" rowspan="1" colspan="1">1,376.58</td><td valign="top" align="left" rowspan="1" colspan="1">1,339.70</td><td valign="top" align="left" rowspan="1" colspan="1">1,281.84</td><td valign="top" align="left" rowspan="1" colspan="1">435.73</td><td valign="top" align="left" rowspan="1" colspan="1">5,066.15</td><td valign="top" align="left" rowspan="1" colspan="1">88.21</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">1,861.22</td><td valign="top" align="left" rowspan="1" colspan="1">1,700.44</td><td valign="top" align="left" rowspan="1" colspan="1">1,732.55</td><td valign="top" align="left" rowspan="1" colspan="1">580.29</td><td valign="top" align="left" rowspan="1" colspan="1">7,038.55</td><td valign="top" align="left" rowspan="1" colspan="1">78.51</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">21.00</td><td valign="top" align="left" rowspan="1" colspan="1">4,276.17</td><td valign="top" align="left" rowspan="1" colspan="1">1,785.81</td><td valign="top" align="left" rowspan="1" colspan="1">4,334.46</td><td valign="top" align="left" rowspan="1" colspan="1">2,270.53</td><td valign="top" align="left" rowspan="1" colspan="1">7,945.56</td><td valign="top" align="left" rowspan="1" colspan="1">40.86</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">7,513.63</td><td valign="top" align="left" rowspan="1" colspan="1">5,632.41</td><td valign="top" align="left" rowspan="1" colspan="1">7,952.93</td><td valign="top" align="left" rowspan="1" colspan="1">3,216.50</td><td valign="top" align="left" rowspan="1" colspan="1">30,514.49</td><td valign="top" align="left" rowspan="1" colspan="1">54.52</td></tr><tr><td rowspan="4" valign="top" align="left" colspan="1">AUC<sub>last</sub> (ng&#183;h/mL)</td><td valign="top" align="left" rowspan="1" colspan="1">2.5</td><td valign="top" align="left" rowspan="1" colspan="1">21.00</td><td valign="top" align="left" rowspan="1" colspan="1">906.77</td><td valign="top" align="left" rowspan="1" colspan="1">1,036.30</td><td valign="top" align="left" rowspan="1" colspan="1">629.48</td><td valign="top" align="left" rowspan="1" colspan="1">243.57</td><td valign="top" align="left" rowspan="1" colspan="1">3,482.59</td><td valign="top" align="left" rowspan="1" colspan="1">98.56</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">1,416.84</td><td valign="top" align="left" rowspan="1" colspan="1">1,547.24</td><td valign="top" align="left" rowspan="1" colspan="1">1,216.97</td><td valign="top" align="left" rowspan="1" colspan="1">441.96</td><td valign="top" align="left" rowspan="1" colspan="1">6,511.81</td><td valign="top" align="left" rowspan="1" colspan="1">84.14</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">21.00</td><td valign="top" align="left" rowspan="1" colspan="1">3,410.48</td><td valign="top" align="left" rowspan="1" colspan="1">1,550.99</td><td valign="top" align="left" rowspan="1" colspan="1">3,496.84</td><td valign="top" align="left" rowspan="1" colspan="1">1,407.75</td><td valign="top" align="left" rowspan="1" colspan="1">7,435.80</td><td valign="top" align="left" rowspan="1" colspan="1">45.16</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">6,333.86</td><td valign="top" align="left" rowspan="1" colspan="1">3,678.42</td><td valign="top" align="left" rowspan="1" colspan="1">6,109.36</td><td valign="top" align="left" rowspan="1" colspan="1">2,958.56</td><td valign="top" align="left" rowspan="1" colspan="1">19,332.44</td><td valign="top" align="left" rowspan="1" colspan="1">50.18</td></tr><tr><td rowspan="4" valign="top" align="left" colspan="1">CL/f (L/h)</td><td valign="top" align="left" rowspan="1" colspan="1">2.5</td><td valign="top" align="left" rowspan="1" colspan="1">21.00</td><td valign="top" align="left" rowspan="1" colspan="1">1.94</td><td valign="top" align="left" rowspan="1" colspan="1">2.46</td><td valign="top" align="left" rowspan="1" colspan="1">1.71</td><td valign="top" align="left" rowspan="1" colspan="1">0.72</td><td valign="top" align="left" rowspan="1" colspan="1">9.49</td><td valign="top" align="left" rowspan="1" colspan="1">82.71</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">2.66</td><td valign="top" align="left" rowspan="1" colspan="1">2.20</td><td valign="top" align="left" rowspan="1" colspan="1">2.80</td><td valign="top" align="left" rowspan="1" colspan="1">0.77</td><td valign="top" align="left" rowspan="1" colspan="1">10.58</td><td valign="top" align="left" rowspan="1" colspan="1">70.17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">21.00</td><td valign="top" align="left" rowspan="1" colspan="1">2.78</td><td valign="top" align="left" rowspan="1" colspan="1">1.03</td><td valign="top" align="left" rowspan="1" colspan="1">2.86</td><td valign="top" align="left" rowspan="1" colspan="1">1.34</td><td valign="top" align="left" rowspan="1" colspan="1">5.17</td><td valign="top" align="left" rowspan="1" colspan="1">37.34</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">3.09</td><td valign="top" align="left" rowspan="1" colspan="1">1.62</td><td valign="top" align="left" rowspan="1" colspan="1">2.96</td><td valign="top" align="left" rowspan="1" colspan="1">1.03</td><td valign="top" align="left" rowspan="1" colspan="1">6.76</td><td valign="top" align="left" rowspan="1" colspan="1">51.00</td></tr><tr><td rowspan="4" valign="top" align="left" colspan="1"><italic toggle="yes">C</italic><sub>max</sub> (ng/mL)</td><td valign="top" align="left" rowspan="1" colspan="1">2.5</td><td valign="top" align="left" rowspan="1" colspan="1">21.00</td><td valign="top" align="left" rowspan="1" colspan="1">157.97</td><td valign="top" align="left" rowspan="1" colspan="1">64.28</td><td valign="top" align="left" rowspan="1" colspan="1">164.52</td><td valign="top" align="left" rowspan="1" colspan="1">61.83</td><td valign="top" align="left" rowspan="1" colspan="1">338.27</td><td valign="top" align="left" rowspan="1" colspan="1">40.19</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">242.22</td><td valign="top" align="left" rowspan="1" colspan="1">101.84</td><td valign="top" align="left" rowspan="1" colspan="1">250.35</td><td valign="top" align="left" rowspan="1" colspan="1">74.06</td><td valign="top" align="left" rowspan="1" colspan="1">490.36</td><td valign="top" align="left" rowspan="1" colspan="1">45.14</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">21.00</td><td valign="top" align="left" rowspan="1" colspan="1">422.66</td><td valign="top" align="left" rowspan="1" colspan="1">119.49</td><td valign="top" align="left" rowspan="1" colspan="1">424.86</td><td valign="top" align="left" rowspan="1" colspan="1">278.10</td><td valign="top" align="left" rowspan="1" colspan="1">693.81</td><td valign="top" align="left" rowspan="1" colspan="1">27.39</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">773.61</td><td valign="top" align="left" rowspan="1" colspan="1">391.64</td><td valign="top" align="left" rowspan="1" colspan="1">671.62</td><td valign="top" align="left" rowspan="1" colspan="1">384.74</td><td valign="top" align="left" rowspan="1" colspan="1">1,787.62</td><td valign="top" align="left" rowspan="1" colspan="1">45.92</td></tr><tr><td rowspan="4" valign="top" align="left" colspan="1"><italic toggle="yes">t</italic><sub>1/2</sub> (hours)</td><td valign="top" align="left" rowspan="1" colspan="1">2.5</td><td valign="top" align="left" rowspan="1" colspan="1">20.00</td><td valign="top" align="left" rowspan="1" colspan="1">5.09</td><td valign="top" align="left" rowspan="1" colspan="1">3.62</td><td valign="top" align="left" rowspan="1" colspan="1">6.25</td><td valign="top" align="left" rowspan="1" colspan="1">0.94</td><td valign="top" align="left" rowspan="1" colspan="1">12.50</td><td valign="top" align="left" rowspan="1" colspan="1">81.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">4.42</td><td valign="top" align="left" rowspan="1" colspan="1">3.09</td><td valign="top" align="left" rowspan="1" colspan="1">4.11</td><td valign="top" align="left" rowspan="1" colspan="1">1.60</td><td valign="top" align="left" rowspan="1" colspan="1">11.87</td><td valign="top" align="left" rowspan="1" colspan="1">63.82</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">21.00</td><td valign="top" align="left" rowspan="1" colspan="1">8.08</td><td valign="top" align="left" rowspan="1" colspan="1">2.25</td><td valign="top" align="left" rowspan="1" colspan="1">7.91</td><td valign="top" align="left" rowspan="1" colspan="1">3.87</td><td valign="top" align="left" rowspan="1" colspan="1">12.13</td><td valign="top" align="left" rowspan="1" colspan="1">29.91</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">6.56</td><td valign="top" align="left" rowspan="1" colspan="1">3.02</td><td valign="top" align="left" rowspan="1" colspan="1">7.32</td><td valign="top" align="left" rowspan="1" colspan="1">2.58</td><td valign="top" align="left" rowspan="1" colspan="1">14.88</td><td valign="top" align="left" rowspan="1" colspan="1">51.19</td></tr><tr><td rowspan="4" valign="top" align="left" colspan="1"><italic toggle="yes">T</italic><sub>max</sub> (hours)</td><td valign="top" align="left" rowspan="1" colspan="1">2.5</td><td valign="top" align="left" rowspan="1" colspan="1">21.00</td><td valign="top" align="left" rowspan="1" colspan="1">2.05</td><td valign="top" align="left" rowspan="1" colspan="1">1.77</td><td valign="top" align="left" rowspan="1" colspan="1">1.68</td><td valign="top" align="left" rowspan="1" colspan="1">0.93</td><td valign="top" align="left" rowspan="1" colspan="1">6.90</td><td valign="top" align="left" rowspan="1" colspan="1">74.14</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">2.09</td><td valign="top" align="left" rowspan="1" colspan="1">2.01</td><td valign="top" align="left" rowspan="1" colspan="1">1.90</td><td valign="top" align="left" rowspan="1" colspan="1">0.78</td><td valign="top" align="left" rowspan="1" colspan="1">7.00</td><td valign="top" align="left" rowspan="1" colspan="1">76.58</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">21.00</td><td valign="top" align="left" rowspan="1" colspan="1">1.62</td><td valign="top" align="left" rowspan="1" colspan="1">1.16</td><td valign="top" align="left" rowspan="1" colspan="1">1.50</td><td valign="top" align="left" rowspan="1" colspan="1">0.83</td><td valign="top" align="left" rowspan="1" colspan="1">5.52</td><td valign="top" align="left" rowspan="1" colspan="1">51.21</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">2.04</td><td valign="top" align="left" rowspan="1" colspan="1">1.69</td><td valign="top" align="left" rowspan="1" colspan="1">1.60</td><td valign="top" align="left" rowspan="1" colspan="1">1.00</td><td valign="top" align="left" rowspan="1" colspan="1">7.00</td><td valign="top" align="left" rowspan="1" colspan="1">63.61</td></tr><tr><td rowspan="4" valign="top" align="left" colspan="1"><italic toggle="yes">V</italic><sub>z</sub>/f (L)</td><td valign="top" align="left" rowspan="1" colspan="1">2.5</td><td valign="top" align="left" rowspan="1" colspan="1">20.00</td><td valign="top" align="left" rowspan="1" colspan="1">14.63</td><td valign="top" align="left" rowspan="1" colspan="1">17.98</td><td valign="top" align="left" rowspan="1" colspan="1">14.61</td><td valign="top" align="left" rowspan="1" colspan="1">3.75</td><td valign="top" align="left" rowspan="1" colspan="1">88.14</td><td valign="top" align="left" rowspan="1" colspan="1">76.07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">16.96</td><td valign="top" align="left" rowspan="1" colspan="1">8.91</td><td valign="top" align="left" rowspan="1" colspan="1">16.64</td><td valign="top" align="left" rowspan="1" colspan="1">5.73</td><td valign="top" align="left" rowspan="1" colspan="1">41.17</td><td valign="top" align="left" rowspan="1" colspan="1">51.74</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">21.00</td><td valign="top" align="left" rowspan="1" colspan="1">32.48</td><td valign="top" align="left" rowspan="1" colspan="1">14.46</td><td valign="top" align="left" rowspan="1" colspan="1">32.95</td><td valign="top" align="left" rowspan="1" colspan="1">11.01</td><td valign="top" align="left" rowspan="1" colspan="1">64.93</td><td valign="top" align="left" rowspan="1" colspan="1">45.99</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">22.00</td><td valign="top" align="left" rowspan="1" colspan="1">29.24</td><td valign="top" align="left" rowspan="1" colspan="1">21.80</td><td valign="top" align="left" rowspan="1" colspan="1">34.29</td><td valign="top" align="left" rowspan="1" colspan="1">7.84</td><td valign="top" align="left" rowspan="1" colspan="1">74.87</td><td valign="top" align="left" rowspan="1" colspan="1">86.58</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-cpaa-8-083"><p><bold>Abbreviations:</bold> AUC<sub>inf</sub>, area under the curve of glibenclamide concentration versus time to infinity; AUC<sub>last</sub>, area under the curve of glibenclamide concentration versus last glibenclamide sample time; CL/f, apparent clearance; <italic toggle="yes">C</italic><sub>max</sub>, maximum glibenclamide concentration; <italic toggle="yes">t</italic><sub>1/2</sub>, glibenclamide half-life; <italic toggle="yes">T</italic><sub>max</sub>, time of glibenclamide maximum concentration; <italic toggle="yes">V</italic><sub>z</sub>/f, apparent volume of distribution; PK, pharmacokinetic; CV, coefficient of variation; h, hours.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-cpaa-8-083" position="float" orientation="portrait"><label>Table 3</label><caption><p>Population PK parameters from the one-compartment and the final one-compartment models</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Population PK parameters</th><th colspan="4" valign="top" align="left" rowspan="1">One-compartment model
<hr/></th><th colspan="4" valign="top" align="left" rowspan="1">Final two-compartment model
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Estimate</th><th valign="top" align="left" rowspan="1" colspan="1">SE</th><th valign="top" align="left" rowspan="1" colspan="1">RSE (%)</th><th valign="top" align="left" rowspan="1" colspan="1">BSV (%CV)</th><th valign="top" align="left" rowspan="1" colspan="1">Estimate</th><th valign="top" align="left" rowspan="1" colspan="1">SE</th><th valign="top" align="left" rowspan="1" colspan="1">RSE (%)</th><th valign="top" align="left" rowspan="1" colspan="1">BSV (%CV)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Ka (1/h)</td><td valign="top" align="left" rowspan="1" colspan="1">2.39</td><td valign="top" align="left" rowspan="1" colspan="1">0.34</td><td valign="top" align="left" rowspan="1" colspan="1">14.39</td><td valign="top" align="left" rowspan="1" colspan="1">51.77</td><td valign="top" align="left" rowspan="1" colspan="1">0.53</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td><td valign="top" align="left" rowspan="1" colspan="1">8.33</td><td valign="top" align="left" rowspan="1" colspan="1">28.57</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CL/f (L/h)</td><td valign="top" align="left" rowspan="1" colspan="1">1.52</td><td valign="top" align="left" rowspan="1" colspan="1">0.12</td><td valign="top" align="left" rowspan="1" colspan="1">7.63</td><td valign="top" align="left" rowspan="1" colspan="1">34.50</td><td valign="top" align="left" rowspan="1" colspan="1">2.16</td><td valign="top" align="left" rowspan="1" colspan="1">0.16</td><td valign="top" align="left" rowspan="1" colspan="1">7.41</td><td valign="top" align="left" rowspan="1" colspan="1">33.91</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">V2/f (L)</td><td valign="top" align="left" rowspan="1" colspan="1">38.90</td><td valign="top" align="left" rowspan="1" colspan="1">2.70</td><td valign="top" align="left" rowspan="1" colspan="1">6.94</td><td valign="top" align="left" rowspan="1" colspan="1">25.77</td><td valign="top" align="left" rowspan="1" colspan="1">11.70</td><td valign="top" align="left" rowspan="1" colspan="1">1.11</td><td valign="top" align="left" rowspan="1" colspan="1">9.49</td><td valign="top" align="left" rowspan="1" colspan="1">23.04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Q/f (L/h)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">3.84</td><td valign="top" align="left" rowspan="1" colspan="1">0.58</td><td valign="top" align="left" rowspan="1" colspan="1">14.97</td><td valign="top" align="left" rowspan="1" colspan="1">65.35</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">V3/f (L)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td><td valign="top" align="left" rowspan="1" colspan="1">6.00</td><td valign="top" align="left" rowspan="1" colspan="1">8.81</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Residual variability variance (%CV)</td><td valign="top" align="left" rowspan="1" colspan="1">0.244 (49.4%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.189 (43.5%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn3-cpaa-8-083"><p><bold>Notes:</bold> CL/f, apparent clearance; Ka, first-order absorption rate; Q/f, apparent intercompartmental clearance; V2/f, apparent volume of the central compartment; V3/f, apparent volume of the peripheral compartment.</p></fn><fn id="tfn4-cpaa-8-083"><p><bold>Abbreviations:</bold> BSV, between-subject variability; CV, coefficient of variation; PK, pharmacokinetic; RSE, relative standard error of the estimate; SE, standard error of the estimate.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-cpaa-8-083" position="float" orientation="portrait"><label>Table 4</label><caption><p>Individual PK parameter estimates from the final two-compartment model</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">ID</th><th valign="top" align="left" rowspan="1" colspan="1">Ka (L/h)</th><th valign="top" align="left" rowspan="1" colspan="1">CL/f (L/h)</th><th valign="top" align="left" rowspan="1" colspan="1">V2/f (L)</th><th valign="top" align="left" rowspan="1" colspan="1">Q/f (L/h)</th><th valign="top" align="left" rowspan="1" colspan="1">V3/f (L)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">0.63</td><td valign="top" align="left" rowspan="1" colspan="1">2.10</td><td valign="top" align="left" rowspan="1" colspan="1">10.03</td><td valign="top" align="left" rowspan="1" colspan="1">2.77</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">0.70</td><td valign="top" align="left" rowspan="1" colspan="1">1.46</td><td valign="top" align="left" rowspan="1" colspan="1">9.26</td><td valign="top" align="left" rowspan="1" colspan="1">2.92</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">0.67</td><td valign="top" align="left" rowspan="1" colspan="1">2.30</td><td valign="top" align="left" rowspan="1" colspan="1">9.94</td><td valign="top" align="left" rowspan="1" colspan="1">3.56</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">0.57</td><td valign="top" align="left" rowspan="1" colspan="1">2.23</td><td valign="top" align="left" rowspan="1" colspan="1">11.42</td><td valign="top" align="left" rowspan="1" colspan="1">6.05</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">0.43</td><td valign="top" align="left" rowspan="1" colspan="1">2.45</td><td valign="top" align="left" rowspan="1" colspan="1">12.85</td><td valign="top" align="left" rowspan="1" colspan="1">6.88</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">0.72</td><td valign="top" align="left" rowspan="1" colspan="1">1.90</td><td valign="top" align="left" rowspan="1" colspan="1">9.88</td><td valign="top" align="left" rowspan="1" colspan="1">5.77</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">0.40</td><td valign="top" align="left" rowspan="1" colspan="1">1.90</td><td valign="top" align="left" rowspan="1" colspan="1">13.41</td><td valign="top" align="left" rowspan="1" colspan="1">1.88</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">0.50</td><td valign="top" align="left" rowspan="1" colspan="1">3.03</td><td valign="top" align="left" rowspan="1" colspan="1">11.80</td><td valign="top" align="left" rowspan="1" colspan="1">1.94</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">0.37</td><td valign="top" align="left" rowspan="1" colspan="1">1.90</td><td valign="top" align="left" rowspan="1" colspan="1">14.61</td><td valign="top" align="left" rowspan="1" colspan="1">2.32</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">0.49</td><td valign="top" align="left" rowspan="1" colspan="1">1.86</td><td valign="top" align="left" rowspan="1" colspan="1">12.28</td><td valign="top" align="left" rowspan="1" colspan="1">2.19</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">0.55</td><td valign="top" align="left" rowspan="1" colspan="1">2.01</td><td valign="top" align="left" rowspan="1" colspan="1">11.31</td><td valign="top" align="left" rowspan="1" colspan="1">2.68</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">0.48</td><td valign="top" align="left" rowspan="1" colspan="1">3.95</td><td valign="top" align="left" rowspan="1" colspan="1">12.66</td><td valign="top" align="left" rowspan="1" colspan="1">6.41</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">0.46</td><td valign="top" align="left" rowspan="1" colspan="1">2.58</td><td valign="top" align="left" rowspan="1" colspan="1">12.61</td><td valign="top" align="left" rowspan="1" colspan="1">7.17</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">0.50</td><td valign="top" align="left" rowspan="1" colspan="1">1.83</td><td valign="top" align="left" rowspan="1" colspan="1">11.32</td><td valign="top" align="left" rowspan="1" colspan="1">1.30</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">0.55</td><td valign="top" align="left" rowspan="1" colspan="1">3.27</td><td valign="top" align="left" rowspan="1" colspan="1">11.26</td><td valign="top" align="left" rowspan="1" colspan="1">7.30</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0.42</td><td valign="top" align="left" rowspan="1" colspan="1">1.23</td><td valign="top" align="left" rowspan="1" colspan="1">13.41</td><td valign="top" align="left" rowspan="1" colspan="1">2.93</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">0.47</td><td valign="top" align="left" rowspan="1" colspan="1">1.81</td><td valign="top" align="left" rowspan="1" colspan="1">13.07</td><td valign="top" align="left" rowspan="1" colspan="1">7.40</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">0.59</td><td valign="top" align="left" rowspan="1" colspan="1">1.06</td><td valign="top" align="left" rowspan="1" colspan="1">10.68</td><td valign="top" align="left" rowspan="1" colspan="1">3.42</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">0.82</td><td valign="top" align="left" rowspan="1" colspan="1">3.18</td><td valign="top" align="left" rowspan="1" colspan="1">8.87</td><td valign="top" align="left" rowspan="1" colspan="1">4.22</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">0.52</td><td valign="top" align="left" rowspan="1" colspan="1">3.35</td><td valign="top" align="left" rowspan="1" colspan="1">11.97</td><td valign="top" align="left" rowspan="1" colspan="1">7.54</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">21</td><td valign="top" align="left" rowspan="1" colspan="1">0.48</td><td valign="top" align="left" rowspan="1" colspan="1">2.23</td><td valign="top" align="left" rowspan="1" colspan="1">11.94</td><td valign="top" align="left" rowspan="1" colspan="1">6.11</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">22</td><td valign="top" align="left" rowspan="1" colspan="1">0.43</td><td valign="top" align="left" rowspan="1" colspan="1">1.75</td><td valign="top" align="left" rowspan="1" colspan="1">12.49</td><td valign="top" align="left" rowspan="1" colspan="1">1.46</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">23</td><td valign="top" align="left" rowspan="1" colspan="1">0.56</td><td valign="top" align="left" rowspan="1" colspan="1">3.31</td><td valign="top" align="left" rowspan="1" colspan="1">11.53</td><td valign="top" align="left" rowspan="1" colspan="1">5.38</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">0.53</td><td valign="top" align="left" rowspan="1" colspan="1">2.31</td><td valign="top" align="left" rowspan="1" colspan="1">11.65</td><td valign="top" align="left" rowspan="1" colspan="1">4.48</td><td valign="top" align="left" rowspan="1" colspan="1">68.10</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-cpaa-8-083"><p><bold>Notes:</bold> CL/f, apparent clearance; Ka, first-order absorption rate; Q/f, apparent intercompartmental clearance; V2/f, apparent volume of the central compartment; V3/f, apparent volume of the peripheral compartment.</p></fn><fn id="tfn6-cpaa-8-083"><p><bold>Abbreviation:</bold> PK, pharmacokinetic; h, hours.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>